
Anthem Biosciences IPO
- Issue price
- ₹570
- Listing price
- ₹723.05
- +26.85%
- Current price
- ₹936.95
- +64.38%
- Subscribed
- 67.42x
- Issue size
- ₹3,395 Cr
- Listed on
- 21 Jul 2025
IPO timeline
- Opens14 JulMon
- Closes16 JulWed
- Allotment17 JulThu
- Refunds18 JulFri
- Demat credit18 JulFri
- Listing21 JulMon
Issue details
- Price band
- ₹540 – ₹570 per share
- Issue size
- ₹3,395 Cr
- Fresh issue
- None
- Offer for sale
- ₹3,395 Cr
- Issue type
- OFS only
- Face value
- ₹2 per share
- Lot size
- 26 shares
- Minimum investment
- ₹14,820
- Listing on
- BSE, NSE
- Exchange code
- ANTHEM · 544449
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 26 | ₹14,820 |
| Retail (Max) | 13 | 338 | ₹1,92,660 |
| S-HNI (Min) | 14 | 364 | ₹2,07,480 |
| B-HNI (Min) | 68 | 1,768 | ₹10,07,760 |
Reservation
- QIB
- 2,97,08,332 shares (50.00% of the Offer)
- NII
- 89,12,500 shares (15.00% of the Offer)
- Retail
- 2,07,95,834 shares (35.00% of the Offer)
- Employee
- 1,58,653 shares (0.27% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on KFin Technologies- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 17 Jul 2025
- Refunds initiated
- 18 Jul 2025
- Shares credited to demat
- 18 Jul 2025
- Listing
- 21 Jul 2025
Grey market premium (GMP)
- Current GMP
- ₹170
- +30.00%
- Estimated listing price
- ₹740
- Issue price ₹570
- Highest
- ₹170
- 21 Jul
- Lowest
- ₹60
- 8 Jul
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 21 Jul 2025 | ₹170 | +30.00% | ₹740 |
| 20 Jul 2025 | ₹167 | +29.00% | ₹737 |
| 19 Jul 2025 | ₹156 | +27.00% | ₹726 |
| 18 Jul 2025 | ₹133 | +23.00% | ₹703 |
| 17 Jul 2025 | ₹140 | +25.00% | ₹710 |
| 16 Jul 2025 | ₹148 | +26.00% | ₹718 |
| 15 Jul 2025 | ₹141 | +25.00% | ₹711 |
| 14 Jul 2025 | ₹110 | +19.00% | ₹680 |
| 12 Jul 2025 | ₹98 | +17.00% | ₹668 |
| 11 Jul 2025 | ₹94 | +16.00% | ₹664 |
| 10 Jul 2025 | ₹106 | +19.00% | ₹676 |
| 9 Jul 2025 | ₹90 | +16.00% | ₹660 |
| 8 Jul 2025 | ₹60 | +11.00% | ₹630 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB192.8x
- NII (HNI)44.7x
- Retail5.98x
- Employee6.99x
Financials
- P/E (pre-issue)
- 70.62
- P/E (post-issue)
- 70.62
- EPS (₹)
- 8.07
- RoE
- 20.82%
- RoCE
- 26.88%
- RoNW
- 20.82%
- PAT Margin
- 23.38%
- EBITDA Margin
- 36.81%
- Debt / Equity
- 0.05
- NAV (₹)
- 43.10
Pre-issue P/E uses the shares outstanding before the IPO; post-issue P/E includes the new shares. Calculated by Be IPO Ready at the issue price.
| Period ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 2,807.58 | 2,398.11 | 2,014.46 |
| Total Income | 1,930.29 | 1,483.07 | 1,133.99 |
| Profit After Tax | 451.26 | 367.31 | 385.19 |
| EBITDA | 683.78 | 519.96 | 446.05 |
| NET Worth | 2,409.86 | 1,924.66 | 1,740.67 |
| Reserves and Surplus | 2,298.05 | 1,815.39 | 1,628.88 |
| Total Borrowing | 108.95 | 232.53 | 125.06 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Anthem Biosciences This IPO | ₹3,395 Cr | 70.62 | 20.82% | 23.38% | 67.42x | +26.85% |
| Sai Life Sciences Mainboard · listed 18 Dec 2024 | ₹3,042.62 Cr | 203.82 | 8.13% | 5.65% | 10.27x | +18.40% |
| Inventurus Knowledge Solutions Mainboard · listed 19 Dec 2024 | ₹2,497.92 Cr | 54.66 | 32% | 20.38% | 52.68x | +42.96% |
| Sagility India Mainboard · listed 12 Nov 2024 | ₹2,106.4 Cr | 61.52 | 0.29% | 11.83% | 3.2x | +3.53% |
| Akums Drugs & Pharmaceuticals Mainboard · listed 6 Aug 2024 | ₹1,856.74 Cr | 13580 | -0.57% | 0.02% | 63.44x | +6.77% |
| Indegene Mainboard · listed 13 May 2024 | ₹1,841.76 Cr | 33.53 | 18.23% | 12.62% | 70.3x | +44.91% |
| Symbiotec Pharmalab Mainboard · listed 1 Sep 2026 | ₹1,757 Cr | 56.81 | 9.48% | 12.60% | 71.26x | 0.00% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
About Anthem Biosciences
Anthem Biosciences Limited was incorporated in 2006. It is a contract research, development and manufacturing organisation. Its operations cover drug discovery, development and manufacturing for emerging biotech firms and large pharmaceutical companies. The company also makes fermentation-based active ingredients. These include probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. On 30 September 2024 it had 196 projects. In the six months to that date it made active ingredients and intermediates for ten commercial molecules, all supported since discovery. The IPO was entirely an offer for sale of Rs 3,395 crore, so the company received no money from it.
Strengths
- Total income rose from Rs 1,133.99 crore in FY2023 to Rs 1,930.29 crore in FY2025.
- The EBITDA margin was 36.81% and the PAT margin was 23.38%.
- Total borrowing fell from Rs 232.53 crore on 31 March 2024 to Rs 108.95 crore on 31 March 2025.
- Return on equity was 20.82% and return on capital employed was 26.88%.
- The company had 196 projects on 30 September 2024.
Risks
- The whole Rs 3,395 crore issue was offer for sale. The company got no fresh money.
- The P/E was 70.62 at the upper band of Rs 570, based on EPS of Rs 8.07.
- Profit after tax fell from Rs 385.19 crore in FY2023 to Rs 367.31 crore in FY2024 before rising in FY2025.
- Contract manufacturing income can be lumpy, and the company made ingredients for only 10 commercial molecules in the six months to 30 September 2024.
- Promoters held 76.87% before the issue and held 74.68% after it.
- Most customers are drug developers, so funding cycles in biotech can reduce the Rs 1,930.29 crore income base.
Promoters and shareholding
Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj
- Promoter holding, pre-issue
- 76.87%
- Promoter holding, post-issue
- 74.68%
Registrar, lead managers and documents
Lead managers
Anthem Biosciences IPO: common questions
1.When does the Anthem Biosciences IPO open and close?
The Anthem Biosciences IPO opens on 14 Jul 2025 and closes on 16 Jul 2025.
2.What is the price band of the Anthem Biosciences IPO?
The price band is ₹540 – ₹570 per share, with a lot size of 26 shares and a minimum investment of ₹14,820.
3.What is the size of the Anthem Biosciences IPO?
The issue size is ₹3,395 Cr (OFS only).
4.What is the GMP of the Anthem Biosciences IPO?
The last reported grey market premium is ₹170 per share as of 21 Jul 2025, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Anthem Biosciences IPO allotment?
The basis of allotment is expected on 17 Jul 2025. Allotment status can be checked with the registrar, KFin Technologies Limited.
6.When will the Anthem Biosciences IPO list?
The shares listed on 21 Jul 2025 on BSE, NSE.
7.Who is the lead manager of the Anthem Biosciences IPO?
The book running lead managers are JM Financial Ltd., JP Morgan India Pvt. Ltd, Citigroup Global Markets India Pvt. Ltd, Nomura Financial Advisory & Securities (India) Pvt. Ltd, and the registrar is KFin Technologies Limited.
8.How can my company launch an IPO like Anthem Biosciences?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393